Brand name: Kimmtrak TM
Active ingredients: tebentafusp
What it is used for
KIMMTRAK is indicated for the treatment of HLA-A02 01-positive adult patients with unresectable or metastatic uveal melanoma.
How to take it
The way to take this medicine is: Intravenous Infusion.
- Store at 2 to 8 degrees Celsius
- Refrigerate
- Do not Freeze
- Do not Shake
- Protect from Light
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Sterile, preservative-free, clear, colourless to slightly yellowish solution in a single-dose vial.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme